ARAndreas Ronit

Andreas Ronit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Ronit has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increased risk of laboratory-confirmed and severe influenza in a contemporary cohort of well-treated persons with HIV compared with matched population controls

    by Josefine Amalie Loft, Magnus Glindvad Ahlström, Andreas Dehlbæk Knudsen, Dina Leth Møller, Andreas Ronit, Thomas Benfield, Børge Grønne Nordestgaard, Shoaib Afzal, Susanne Dam Nielsen

    Background: While influenza burden is increased among untreated persons with HIV (PWH), it is unclear if this also applies to well-treated PWH. We investigated the incidence of laboratory-confirmed influenza and severe influenza, i.e. influenza-associated hospitalization and death, in a contemporary cohort of virologically suppressed PWH and matched controls from the Danish general population, and whether HIV status was associated with these outcomes. Methods: We included 1,005 virologically suppressed PWH from the Copenhagen Comorbidity in HIV Infection Study and 10,050 matched controls from the Copenhagen General Population Study. Outcome data were obtained from national registries. Incidence rates (IR) per 1,000 person-years (PY) and incidence rate ratios (IRR) were calculated, and cumulative incidences were estimated accounting for competing risks. Associations between HIV status and outcomes were explored using Fine-Gray models. Results: Follow-up time was 6,286 PY in PWH and 60,596 PY in matched controls for laboratory-confirmed influenza, and 5,890 PY and 56,015 PY for severe influenza. The IRs per 1,000 PY of laboratory-confirmed influenza were 4.1 (95%CI 2.7-6.1) in PWH and 1.8 (95%CI 1.5-2.1) in controls (IRR 2.3, 95%CI 1.5-3.6, p<0.001). For severe influenza, IRs were 1.9 (95%CI 0.9-3.3) and 0.5 (95%CI 0.4-0.7), and IRR 3.6 (95%CI 1.8-7.2, p<0.001). In competing risk regression models, HIV status was associated with increased risk of laboratory-confirmed influenza (subdistribution hazard rate (sHR) 2.5, 95%CI: 1.6-3.8, p<0.001) and severe influenza (sHR 3.9, 95%CI: 2.0-7.8, p<0.001). Conclusions: Even well-treated PWH have higher risk of laboratory-confirmed and severe influenza than the general population, highlighting the importance of preventive measures.

  • Open Access

    Impaired lung function as an important risk factor for blood stream infections

    by Magnus G. Ahlström, Andreas Ronit, Børge G. Nordestgaard, Susanne D. Nielsen, Shoaib Afzal

  • Open Access

    Prevalence and Risk Factors of Preserved Ratio Impaired Spirometry in People With HIV and Matched Population Control Participants

    by Safura-Luise Heidari, Josefine Amalie Loft, Yunus Çolak, Shoaib Afzal, Børge G. Nordestgaard, Thomas Benfield, Ken M. Kunisaki, Susanne Dam Nielsen, Andreas Ronit


  • Open Access

    Composition and diversity of the pulmonary microbiome in acute respiratory distress syndrome: a systematic review

    by Katrine Schneider, Johan Ulrich Ulrichsen, Amalie Nimand Westphal, Ulrik Winning Iepsen, Andreas Ronit, Ronni R. Plovsing, Ronan M. G. Berg

    The pulmonary microbiome plays a crucial role in respiratory health and disease, with growing evidence suggesting its involvement in the pathophysiology of acute respiratory distress syndrome (ARDS). This systematic review synthesises current findings on primarily the composition of the lung microbiome in ARDS patients, and secondarily evaluates the microbial diversity, bacterial abundance and their potential clinical implications on disease severity, ventilator-free days and mortality. A comprehensive literature search identified 11 studies, including 660 patients, 466 of whom had ARDS, examining lung microbial alterations in ARDS using different sequencing technologies. While studies reported different, but consistent changes in microbial compositions, findings on diversity varied across studies. Trends suggest an increased prevalence of specific opportunistic pathogens, particularly members of the gut-associated Enterobacteriaceae family, which was also shown to be associated with fewer ventilator-free days and mortality, although differences in patient populations, study methodologies, and sequencing techniques influenced the results. The relationship between the pulmonary microbiome and clinical outcomes, remains an area of active investigation. Clinical trial Registration:the PROSPERO ID CRD42023467660.


  • Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis

    by Ioannis Konstantinidis, Richard H. Zou, Spyridon N. Papageorgiou, Andreas Ronit, M. Bradley Drummond, Ken M. Kunisaki, Kristina Crothers, S. Mehdi Nouraie, Alison Morris

    Rationale: Obstructive lung disease (OLD) pathogenesis includes inhalational (e.g., smoking) and noninhalational mechanisms (e.g., infections). Human immunodeficiency virus (HIV) has been suggested as a novel OLD risk factor. Substantial data have recently emerged about its effects on lung function and structure, especially in low- to middle-income countries and regarding longitudinal lung function. Objectives: To assess the association of HIV infection with OLD, impaired gas exchange, and emphysema. Methods: In this systematic review and meta-analysis, we searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Science, Scopus, Cumulative Index to Nursing and Allied Health Literature, and Global Index Medicus through April 2023 for controlled and observational studies of people living with and without HIV reporting pulmonary function and/or emphysema. Primary outcomes were OLD by spirometry, gas exchange impairment by diffusing capacity of the lung for carbon monoxide, and visual emphysema by computed tomography. We performed random-effects meta-analyses using odds ratios (ORs) with 95% confidence intervals (CIs). This study was registered in PROSPERO (CRD42021268498). Results: We included 95 publications pertaining to 43 unique studies. HIV was associated with OLD (OR, 1.29; 95% CI, 1.02–1.63), impaired gas exchange (OR, 2.63; 95% CI, 0.96–7.24), emphysema (OR, 1.46; 95% CI, 1.02–2.09), and faster lung function decline. OLD risk was greatest in Africans with HIV. There were no gas exchange or emphysema data from Africa. The certainty of evidence was low to very low, primarily because of studies’ observational design. Conclusions: People living with HIV have increased risk for OLD, gas exchange impairment, faster lung function decline, and emphysema. OLD risk in HIV varies regionally. We recommend that both spirometry and diffusing capacity of the lung for carbon monoxide be measured in people living with HIV and respiratory symptoms. Future studies should develop and validate HIV-specific screening and case-finding strategies for chronic lung disease.


  • Prevalence and etiology of ventilator‐associated pneumonia during the COVID‐19 pandemic in Denmark: Wave‐dependent lessons learned from a mixed‐ICU

    by Joanna Grzywacz, Magnus G. Ahlström, Thomas Benfield, Ronan M. G. Berg, Ronni R. Plovsing, Andreas Ronit

    Background: Ventilator‐associated pneumonia (VAP) may be a particular concern in patients with severe coronavirus disease 2019 (COVID‐19). We aimed to determine the prevalence and etiology of VAP in critically ill COVID‐19 patients in a Danish intensive care unit (ICU) during the first three waves of the COVID‐19 pandemic and to study associations between dexamethasone (DXM) use and development of VAP.Methods: In an observational single‐center study patients were retrospectively screened for VAP including causative pathogens, use of DXM and commonly used antibiotics. Diagnosis of VAP required invasive mechanical ventilation (IMV) >48 h with presence of a new bacterial agent and clinical signs of infection. For analysis, common descriptive statistics were applied. Cox proportional hazards models were used to analyze the association between DXM use and VAP.Results: VAP was detected in 53/119 (44.5%) mechanically ventilated patients across all three COVID‐19 waves. Median length of IMV for VAP patients was 24 [15–41] days, and 3 out of 4 were males. VAP was most prevalent (47.0%) during the second wave. Common pathogens included Klebsiella pneumoniae (24.5%), Enterobacter aerogenes (17.0%) and Pseudomonas aeruginosa (13.2%), Staphylococcus aureus (13.2%), and Escherichia coli (13.2%). A change from Gram‐negative bacteria only to a combination of Gram‐positive and Gram‐negative bacteria was observed in the second wave compared to first. Use of DXM was not associated with VAP (adjusted hazard ratio 1.63 95% CI: 0.84–3.17).Conclusion: The prevalence of VAP was high across all three COVID‐19 waves and showed a different distribution of pathogens between the first and second wave. Use of DXM was not associated with VAP development. Further and larger studies are needed to understand the risk factors associated with VAP in patients with COVID‐19.


  • Open Access

    Lung Function Trajectories in Mild COVID-19 With 2-year Follow-up

    by Katrine K Iversen, Andreas Ronit, Magnus G Ahlström, Børge G Nordestgaard, Shoaib Afzal, Thomas Benfield

    Background: The long-term pulmonary sequelae of mild coronavirus disease 2019 (COVID-19) remains unknown. In this study, we aimed to characterize lung function trajectories in individuals with mild COVID-19 from preinfection to 2 years postinfection. Methods: We reinvited participants 2 years after infection from our matched cohort study of the Copenhagen General Population who had initially been examined 5.4 months after infection. We repeated lung tests and questionnaires. Linear mixed models were used to estimate dynamics in lung volumes in individuals with COVID-19 patients versus uninfected controls over two intervals: from pre-infection to 6 months postinfection and 6 months postinfection to 2 years postinfection. Results: 52 individuals (48.6%) attended the 2-year examination at median 1.9 years (interquartile range, 1.8–2.4) after COVID-19, all with mild infection. Individuals with COVID-19 had an adjusted excess decline in forced expiratory volume in 1 second (FEV1) of 13.0 mL per year (95% confidence interval [CI], −23.5 to −2.5; P = .02) from before infection to 6 months after infection compared to uninfected controls. From 6 to 24 months after infection, they had an excess decline of 7.5 mL per year (95% CI, −25.6–9.6; P = .40). A similar pattern was observed for forced vital capacity (FVC). Participants had a mean increase in diffusing capacity for carbon monoxide (DLco) of 3.33 (SD 7.97) between the 6- and 24-month examination. Conclusions: Our results indicate that mild COVID-19 infection affects lung function at the time of infection with limited recovery 2 years after infection.


  • Risk of Respiratory Symptoms in People With HIV Compared to HIV-Uninfected Persons: A Systematic Review and Meta-Analysis

    by I. Konstantinidis, R.H. Zou, S.N. Papageorgiou, A. Ronit, M.B. Drummond, K.M. Kunisaki, K.A. Crothers, S.M. Nouraie, A. Morris

  • Open Access

    Lung Abnormalities in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: An Analysis of Paired Computed Tomography Scans Before and After Infection

    by Katrine K Iversen, Andreas Ronit, Thomas S Kristensen, Shoaib Afzal, Jelena Jankovic, Anna Kalhauge, Magnus G Ahlström, Børge G Nordestgaard, Klaus F Kofoed, Thomas Benfield

    Studies on the pulmonary consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are impeded by limited access to pre–SARS-CoV-2 examinations. We invited Copenhagen General Population Study participants with a confirmed SARS-CoV-2 polymerase chain reaction (PCR) test during the first and second coronavirus disease 2019 waves in Denmark for a repeat chest computed tomography (CT) scan. Paired CT scans were independently assessed for interstitial and noninterstitial abnormalities by 2 trained radiologists. A semiquantitative CT score (ranging from 0 to 20) was used to quantify the extent of interstitial abnormalities. Of 111 SARS-CoV-2–infected individuals, 102 (91.2%) experienced symptoms and 12 (11.2%) were hospitalized. Follow-up examination was performed at median of 5.4 (interquartile range, 4.1–7.8) months after a positive SARS-CoV-2 PCR test. Of 67 individuals with paired CT scans, ground glass opacities and reticulation were present in 31 (46.3%) individuals post–SARS-CoV-2 compared to 23 (34.1%) pre–SARS-CoV-2 (mean CT score, 3.0 vs 1.3; P = .011). Results were similar for nonhospitalized individuals. We did not detect development of bronchiectasis, emphysema, or nodules. SARS-CoV-2 infection in predominantly nonhospitalized individuals with mild disease was associated with a small increase in only interstitial lung abnormalities.